DocMorris AG (ZRSEF)
95.77
0.00 (0.00%)
USD |
OTCM |
Apr 15, 16:00
DocMorris Cash from Investing (TTM): 243.96M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 243.96M |
| June 30, 2023 | 225.31M |
| December 31, 2022 | -93.21M |
| June 30, 2022 | -69.81M |
| December 31, 2021 | -73.45M |
| June 30, 2021 | -184.17M |
| December 31, 2020 | -216.69M |
| June 30, 2020 | -90.50M |
| Date | Value |
|---|---|
| December 31, 2019 | -143.09M |
| June 30, 2019 | -242.86M |
| December 31, 2018 | -141.04M |
| June 30, 2018 | -69.71M |
| December 31, 2017 | -63.03M |
| June 30, 2017 | -21.83M |
| December 31, 2016 | -23.46M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-242.86M
Minimum
Jun 2019
243.96M
Maximum
Dec 2023
-64.45M
Average
-91.85M
Median
Cash from Investing (TTM) Benchmarks
| AC Immune SA | 73.11M |
| CRISPR Therapeutics AG | 374.65M |
| Addex Therapeutics Ltd | -0.0064M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 49.71M |